Patent: 10,022,427

Summary for Patent: 10,022,427

Title:	Interferon lambda-antibody complexes
Abstract:	The present invention concerns methods and compositions for forming complexes of interferon-.lamda. with an antibody or antigen-binding antibody fragment. In preferred embodiments, the interferon-.lamda. and the antibody or fragment are fusion proteins, each comprising a dimerization and docking domain (DDD) moiety from human protein kinase A or an anchor domain (AD) moiety from an A-kinase anchoring protein (AKAP). In more preferred embodiments, the interferon-antibody complex is more efficacious for treatment of cancer, asthma, Alzheimer\'s disease, multiple sclerosis or viral infection than interferon-.lamda. alone, antibody alone, or the combination of unconjugated interferon-.lamda. and antibody.
Inventor(s):	Chang; Chien-Hsing (Downingtown, PA), Goldenberg; David M. (Mendham, NJ), Liu; Donglin (Kendall Park, NJ)
Assignee:	IBC Pharmaceuticals, Inc. (Morris Plains, NJ)
Application Number:	14/997,843
Patent Claims:	see list of patent claims

United States Patent 10,022,427: What the Claims Actually Cover and Where the Landscape Pushes Back

US Patent 10,022,427 is framed around a “targetable interferon” delivered by a engineered, modular interferon-fusion “interferon-antibody complex.” The core concept is not a new interferon, but a specific molecular architecture: human interferon-lambda fused to one element (AD or DDD), and an antibody (or antigen-binding fragment) fused to the complementary element (DDD or AD). The claims then cascade into broad disease targeting, broad antigen selection, and optional combination therapy.

At the practical level, the patent’s enforceability hinges on whether its defining structural constraints are truly novel in the relevant prior art and whether the claims are drafted tightly enough to avoid being read onto earlier constructs that used docking/anchoring pairs, multivalent binding systems, or interferon-lambda targeting.

---

What are the claim-defining elements in US 10,022,427?

Claim 1 (and mirrored claim 16): the “interferon-antibody complex” construction

Claim 1 is the structural anchor. It requires:

1) A first fusion protein

• Contains human interferon-lambda attached to an anchor domain (AD) moiety from an AKAP (A-kinase anchoring protein)
• The AD amino acid sequence is selected from a long list of SEQ ID NOs (SEQ ID NO:3, 4, 7, 8, 9, 10, 32-84, etc.).

2) A second fusion protein

• Contains an antibody or antigen-binding antibody fragment attached to a dimerization and docking domain (DDD) moiety from human PKA RII.alpha.

3) A complex formation rule

• Two copies of the DDD form a dimer that binds to the AD moiety to form the interferon-antibody complex.

4) Therapeutic use

• Administer a therapeutically effective amount of that complex to a subject with cancer or viral infection.

This architecture matters because it narrows the inventive hook to a precise protein interaction geometry: DDD dimer binds AD to “lock” the interferon-lambda to the antibody-binding module.

Claim 2: interferon-lambda selection

Interferon-lambda is limited to:

• hIFN-λ1, hIFN-λ2, hIFN-λ3

Claim 3-5: antigen and antibody breadth

• Claim 3 enumerates a very wide antigen universe (from tumor antigens like EGFR/CEACAM5/TROP-2 and immune targets like CD markers to cytokine pathway targets and complement components).
• Claim 4 narrows to a smaller list (TROP-2, CEACAM5/6, HLA-DR, CD19/CD20/CD22/CD52/CD74, EGFR).
• Claim 5 narrows the antibody selection further to specific antibody designations (hLL1, hLL2, RFB4, hRS7, hPAM4, hMN-3, hMN-14, hMN-15, hMu-9, Immu31, hL243, hA19, hA20, alemtuzumab, hR1).

Claim 6: antibody fragment formats

• Fab, Fv, scFv, dAb.

Claim 7-11: optional combination therapy and extensive add-on pharmacology

Claim 7 allows administering an additional therapeutic agent. Claim 8 expands that list to almost any modality used in oncology and immunotherapy (second antibody/fragments, interferons, cytokines/chemokines, siRNA, radionuclides, toxins, etc.).

Claim 9 and Claim 10 and Claim 11 provide expansive, explicit drug/toxin/anti-angiogenic selections. This breadth does not define the core molecular construct; it expands the claim’s “method” scope so that combination regimens do not fall outside literal infringement.

Claim 12-14: disease categories

• Claim 12 lists many cancers.
• Claim 13 lists many viruses.
• Claim 14 specifically includes chronic hepatitis C.

Claim 15: antibody specificity by disease family

Claim 15 provides another broad mapping of antibody types (anti-HIV, anti-HCV, anti-malarial, anti-bacterial, anti-fungal, etc.).

Claim 17: a different delivery model inside the same patent family

Claim 17 shifts from “administer the interferon-antibody complex” to a two-part system:

• Administer a bispecific antibody complex with:
  • one arm fused to PKA RII.alpha DDD
  • another arm fused to AKAP AD
  • the two binding specificities are: disease-associated antigen and hapten
• Administer a targetable construct containing human interferon-lambda + at least one copy of the hapten
• The targetable construct binds the bispecific antibody to deliver interferon-lambda to diseased cells.

This matters for landscape analysis because it adds a second conceptual inventive pathway: not just AD-DDD complexation, but also hapten-mediated targeting layered on top.

---

What is the key novelty thesis implied by the claims?

US 10,022,427 claims a modular, “reversible assembly” delivery system for interferon-lambda, assembled by a specific interaction pair:

• AKAP-derived AD (selected from specified SEQ IDs)
• PKA RII.alpha-derived DDD (two copies dimerize)

The novelty thesis appears to be:

• interferon-lambda is used, but the “delivery engine” is the AD-DDD docking pair architecture linked to antibody targeting.

This is a “platform” claim style: it is broad in antigen and indication, but narrow in the molecular connection rules.

---

How broad are the claims, and where is the practical narrowing?

Breadth: indications and target antigens

• Cancer scope covers common solid tumors and hematologic malignancies.
• Viral scope covers many major virus families, including chronic HCV.
• Antigen lists are large and include many widely pursued targets (EGFR, HER2-like antigens via CEACAM5/6, CD markers, complement factors, etc.).

Narrowing: structural constraints

The enforceable narrowing is concentrated in:

• the fusion logic (interferon-lambda must attach to AD; antibody must attach to DDD or vice versa in claim 16)
• the specific AD sequences (fixed set of SEQ ID NOs)
• the DDD is from human PKA RII.alpha
• the complex formation rule (two DDD copies dimerize and bind AD)

In practice, this means:

• a competitor can potentially avoid literal infringement by using a different docking pair, different anchor/docking domains, different interferon attachment strategy, or different dimerization geometry (even if the biological outcome is similar).

But method-of-treatment claims also create risk if the competitor’s formulation still “falls within” the interaction structure and produces the same assembled complex.

---

What would likely be the critical prior art categories?

Because the claims are heavily defined by protein fusion and docking mechanics, the landscape is likely to include several prior art buckets:

1) Interferon-lambda therapeutics

If interferon-lambda therapy itself is prior art, those references do not by themselves destroy novelty. They only matter insofar as they disclose fused interferon-lambda delivery formats that match the AD-DDD docking architecture.

2) Antibody-drug conjugates and immunocytokines

Immunocytokines and antibody-cytokine fusions are extensive in oncology. The key question is whether any prior art uses:

• interferon-lambda
• antibody-binding fragments
• a docking/anchor pair that assembles into an interferon-antibody complex
• the specific AD and DDD sequences and interaction rule.

3) Docking-domain and dimerization systems

Docking domains and split-binding assembly systems are common in targeted protein delivery. The novelty risk increases if earlier patents disclose:

• AKAP-derived anchoring motifs
• PKA RII.alpha dimerization/docking motifs
• fusion proteins assembled by that specific interaction pair.

The claims’ strength depends on whether the specific AD sequences and PKA RII.alpha DDD were previously disclosed in the same “interferon-lambda + antibody” context.

4) Bispecific/hapten systems

Claim 17 mixes bispecific antibody targeting with hapten-mediated targeting. The risk is whether earlier bispecific/hapten delivery patents already exist that use:

• an antibody arm for disease antigen
• a hapten arm
• an interferon-lambda bearing hapten construct

If that combination existed with any other cytokine, the remaining question is whether interferon-lambda was already taught in combination with the same hapten/bispecific architecture.

---

Where the claims are vulnerable in litigation or prosecution?

1) “Selected from SEQ ID NO list” breadth plus sequence dependence

The claim includes a large discrete set of AD sequences. Large lists sometimes create:

• interpretive issues (scope depends on precise sequence boundaries)
• obviousness risk if each listed AD sequence is known and swapping among them is routine for skilled persons.

But the flip side is that if those SEQ IDs are tightly defined and not previously disclosed in the same context, the list can preserve novelty.

2) Interaction rule could be read broadly

Claim 1 requires two DDD copies form a dimer binding the AD moiety. If prior art discloses assemblies where PKA RII.alpha motifs dimerize with AKAP motifs generally, an examiner or challenger could argue functional equivalence, even if the exact fusion context differs.

3) Antigen and antibody lists create “obvious application” exposure

The claim’s antigen breadth can look like:

• “use any targeting antibody against any antigen, keep the rest the same” If the docking-mediated interferon attachment is the inventive point, then using that point with many antibodies can be challenged as an obvious variation.

4) Combination-therapy provisions can be attacked as non-limiting

Claim 7-11 allow adding essentially any anti-cancer modality. Those added agent lists rarely distinguish the molecular invention; they mainly expand method coverage. That can raise enablement or claim scope issues in some settings, depending on how the specification supports each modality.

5) Claim 17’s two-part system is a second claim theory

Claim 17 shifts to hapten delivery layered on top of AD-DDD bispecific binding. If prior art exists for either:

• bispecific + hapten delivery of cytokines
• cytokines targeting via hapten moieties then Claim 17 can be attacked as predictable combination unless the specification tied interferon-lambda to that architecture with specific technical advantages.

---

How to map the claim architecture to the competitive “design-around” space

From a business-risk standpoint, the highest-value competitor counter-scenarios are:

1) Different anchoring/docking pair

• Use a non-AKAP AD and/or non-PKA RII.alpha DDD.
• Preserve assembled docking behavior but change the interacting motifs.

2) Different assembly geometry

• Avoid “two DDD copies form a dimer that binds AD” by changing valency or docking rules.
• Use direct fusion rather than assembling an interferon-antibody complex through docking.

3) Different interferon attachment

• Fuse interferon-lambda to a different scaffold than the AD moiety.
• Attach the antibody to a different intermediate that avoids the AD-DDD pairing.

4) Different targeting modality

• Keep interferon-lambda and antibodies but use:
  • antibody-drug conjugates
  • immunoliposomes
  • bispecific with a different capture handle (non-hapten or different hapten) to avoid the exact Claim 17 two-part constraints.

---

Patent landscape dynamics to monitor (without relying on new factual allegations)

The landscape relevance typically clusters around these prosecution and enforcement levers:

• Is there earlier art that already teaches AKAP-AD and PKA RII.alpha DDD docking in a therapeutic fusion context?
  If yes, US 10,022,427 must rely on interferon-lambda and/or antibody assembly specifics.

• Is there earlier art for interferon-lambda immunocytokines or targeted interferon-lambda constructs?
  If yes, the patent must distinguish on the AD-DDD assembly mechanism.

• Does the SEQ ID list correspond to previously used motifs in non-interferon therapeutic systems?
  If yes, those motifs might be obvious swaps.

• Does the claim bundle overlap with other pending or granted patents in the same chemical-protein delivery space?
  Even if US 10,022,427 is valid, the freedom-to-operate depends on whether alternative patents block design-around approaches.

---

Key Takeaways

• US 10,022,427 is built around a modular therapeutic assembly: interferon-lambda fused to an AKAP-derived AD and an antibody fused to a PKA RII.alpha-derived DDD, where two DDD copies dimerize to bind AD and form an interferon-antibody complex.
• The patent’s breadth comes from expansive lists of antigens, antibodies, cancers, viruses, and add-on combination agents; its enforceable narrowing is concentrated in the specific AD sequence set (SEQ ID NOs) and the DDD/AD interaction geometry.
• Claim 17 adds a second delivery mode: a bispecific antibody with antigen and hapten binding plus a hapten-interferon-lambda construct, which increases the number of plausible prior-art combinations and raises combination-obviousness risk.
• The most credible design-arounds are to change the docking/anchoring pair, alter assembly valency/geometry, or replace hapten capture with a different targeting handle or architecture.

---

FAQs

1) What is the core invention in US 10,022,427?
A docked assembly of interferon-lambda with an antibody-binding module using AKAP-derived AD and PKA RII.alpha-derived DDD, where two DDD copies dimerize and bind AD to form the therapeutic complex.

2) Does the patent claim all interferon-lambda therapies?
No. It claims methods that specifically require the AD-DDD-linked interferon-antibody complex (and, for claim 17, the bispecific-hapten delivery arrangement).

3) How constrained is the antibody targeting?
Claim 1 is constrained by the requirement that the antibody (or fragment) is attached to the DDD moiety, but it is broad on which antibodies and antigen targets are permitted via long enumerated lists.

4) What is the main litigation vulnerability for broad method claims like these?
Whether prior art already discloses the same protein interaction pair (or functionally equivalent docking architecture) and whether swapping in interferon-lambda and different antibodies is obvious.

5) What are the most practical design-arounds?
Change the docking/anchoring domains, avoid the required two-copy DDD dimer-to-AD binding rule, or use a different targeting mechanism than the claimed hapten-bispecific approach in claim 17.

---

References

[1] United States Patent 10,022,427 (claims provided in prompt text).

Details for Patent 10,022,427

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	January 10, 1978		2036-01-18
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	May 07, 2001		2036-01-18
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	November 14, 2014		2036-01-18